Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.

@article{Rutter2011IntravenousSA,
  title={Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.},
  author={Karoline Rutter and T M Scherzer and Sandra Beinhardt and Heidrun Kerschner and Albert Friedrich Staettermayer and Harald Hofer and Theresia Popow-Kraupp and Petra Steindl-Munda and P Ferenci},
  journal={Antiviral therapy},
  year={2011},
  volume={16 8},
  pages={1327-33}
}
BACKGROUND Intravenous silibinin (ivSIL) is a potent antiviral agent against HCV. In vitro silibinin (SIL) inhibits viral replication, possibly by inhibiting HCV RNA polymerase. In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (standard of care [SOC]). METHODS A total of 27 treatment-naive patients with <2 log drop in viral load after 12 weeks or still detectable HCV RNA after 24 weeks of SOC treatment (mean age… CONTINUE READING